Trials / Unknown
UnknownNCT05691114
Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson's Disease
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Shanghai East Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm, dose escalation study, to explore the safety, tolerability and efficacy of human amniotic epithelial stem cells (hAESCs) for idiopathic Parkinson's disease (PD).
Detailed description
hAESCs will be administration through the Ommaya reservoir implanted into the lateral ventricle of subjects with idiopathic PD. This dose escalation will be followed by an exploratory expansion phase in 3 cohorts. * Dose A (5×10\^7 cells/dose) * Dose B (1.0×10\^8 cells/dose) * Dose C (1.5×10\^8 cells/dose).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | hAESCs | human Amniotic Epithelial Stem Cells |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2025-02-01
- Completion
- 2026-02-01
- First posted
- 2023-01-19
- Last updated
- 2023-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05691114. Inclusion in this directory is not an endorsement.